Introduction
Epstein-Barr virus (EBV)-associated lymphomatoid granulomatosis (LYG) is an uncommon B-cell lymphoproliferative disorder (LPD) with distinct histopathologic and clinical characteristics that set it apart from other EBV+ B-cell LPDs and lymphomas. Because T-cells dominated the pathologic examination when this condition was first characterized in 1972 by Liebow et al., it was initially believed to be a T-cell disorder. It was later discovered that LYG was a B-cell LPD secondary to EBV with a noticeable angiocentric T-cell infiltration. LYG can be distinguished from other EBV-associated lesions using specific clinicopathologic characteristics because EBV is linked to many malignant and nonmalignant B-cell illnesses.
What Happens in Lymphomatoid Granulomatosis?
The abnormal cells invade tissues and start building up (creating lesions or nodules). The lesions or nodules harm or destroy the blood vessels inside these tissues. The most typical site of involvement in lymphomatoid granulomatosis is the lungs. Coughing, dyspnea (shortness of breath), and tightness in the chest are common symptoms. Skin, the central nervous system, the kidneys, and the liver are other body parts regularly impacted. B-cells (B lymphocytes), disordered cells in lymphomatoid granulomatosis, are infected with the Epstein-Barr virus. The two main categories of lymphocytes are T-lymphocytes and B-lymphocytes, which can either directly kill microbes or work with other lymphocytes to neutralize specific invaders by producing certain antibodies. Individuals with lymphomatoid granulomatosis, which is brought on by the development of abnormal B-cells, may later develop B-cell lymphoma, a kind of non-Hodgkin lymphoma. Cancer of the lymphatic system is referred to as lymphoma in general.
What Are the Symptoms of Lymphomatoid Granulomatosis?
Individuals with lymphomatoid granulomatosis experience a wide range of symptoms and disease progression. In rare cases, the illness will spontaneously go away in those affected (spontaneous remission), but more often than not, it will worsen and lead to potentially fatal complications. In chest radiographs, it can occasionally be an accidental and asymptomatic finding. Some of the symptoms are as follows:
-
Cough.
-
Dyspnea.
-
Fever.
-
Malaise.
-
Weight loss.
-
Fatigue.
-
Subcutaneous nodules (tiny growths or bumps beneath the skin's surface).
-
Papules (elevated bumps in the skin).
-
Macules (flat discolored lesions in the skin).
-
Patchy reddish rash on the skin.
-
Changes in mental state.
-
Headache.
-
Seizures.
-
Hemiparesis (paralysis on one side of the body).
-
Ataxia (inability to coordinate voluntary movements).
-
Hepatomegaly (enlarged liver).
What Are the Causes of Lymphomatoid Granulomatosis?
It is uncertain what specifically causes lymphomatoid granulomatosis. Those with immune system disorders, such as HIV (human immunodeficiency virus) infection and Wiskott-Aldrich syndrome (an uncommon genetic disorder affecting the immune system of boys), are more likely to develop lymphomatoid granulomatosis than healthy people. The reason for immunological dysfunction in the majority of individuals is unknown. Lymphomatoid granulomatosis is most likely caused by a confluence of immunodeficiency, genetic, and family factors. Although the type of therapy employed varies, it typically focuses on removing EBV-infected B-cells or enhancing the immune system. It has been challenging to classify lymphomatoid granulomatosis. The condition was first thought to be a harmless process with a chance of developing malignant lymphoma. T-cells were thought to be faulty cells by researchers. Researchers have discovered that the faulty cells in lymphomatoid granulomatosis are B-cells exposed to the Epstein-Barr virus. The majority of the cells in the tissues, nevertheless, are T-cells responding to the aberrant, EBV-infected B-cells. The Epstein-Barr virus, which often has no long-lasting symptoms and is widespread among the general population, is responsible for infectious mononucleosis (IM) (a contagious disease caused by EBV), a condition for which it is quite well-known.
How Is Lymphomatoid Granulomatosis Diagnosed?
A thorough clinical examination, a full patient history, and many specialized tests, including the surgical removal and microscopic inspection (biopsy) of tissue samples collected from the affected organ, are used to determine the diagnosis of lymphomatoid granulomatosis. However, a skin biopsy may not be accurate because the distinctive aberrant cells may not be present.
The results of some X-ray examinations, such as CT (computed tomography) scans, may help with diagnosis. For example, the degree of lymphomatoid granulomatosis can be determined through a CT scan of the lungs or another affected organ. In addition, lumbar puncture (LP) and brain magnetic resonance imaging (MRI) should be done to exclude central nervous system involvement.
How Is Lymphomatoid Granulomatosis Treated?
Unknown treatment options exist for people with lymphomatoid granulomatosis. While long-term survival without treatment and spontaneous remission have both happened in patients with mild disease cases, observation may be advised for those with it. Nonetheless, treatment is typically advised. Depending on the severity of the ailment, treatment suggestions are made. Pathologically speaking, lymphomatoid granulomatosis is categorized into three classes (I, II, and III), depending on the quantity of EBV+ B-cells and the degree of necrosis.
Low-Grade LYG:
-
Observation and Immunosuppression Withdrawal - In LYG, iatrogenic immunosuppressive causes should be minimized or eliminated if at all possible, and individuals with low-grade disease may be tracked for regression. Some individuals with low-grade LYG and little disease burden may be qualified for an initial term of surveillance even in the absence of a treatable source of immune failure. Most of these individuals eventually require disease-directed therapy; however, a small percentage may demonstrate no progression or spontaneous remission.
-
IFN - α (Interferon Alpha) - Patients with low-grade LYG in the prospective NCI (National Cancer Institute) research got IFN- as their primary therapy, first at a dose of 7.5 million international units (MIU) three times per week (TIW), which was increased as tolerated every one to two weeks, and continued for one year after the best response.
-
Other Immunotherapies - It is believed that EBV+ lymphomas have developed tolerogenic pathways that allow immune evasion. Immune surveillance plays a crucial regulatory function in the development of malignancy. One way abnormal cells can avoid immune monitoring is by upregulating the PD-L1 (programmed death-ligand 1) protein and EBV+ B-LPDs have been shown to express PD-L1 at high levels. It has been demonstrated that inhibiting programmed death 1 (PD-1) interaction with its ligands, PD-L1 and PD-L2, can restore tumor-specific effector T cell inactivation and activate anticancer responses. In LYG and other EBV+ B-LPDs, PD-1 inhibition may be a successful therapeutic approach.
High-Grade LYG: High-grade illness is thought to be an independent process that is less likely to respond to substances that boost the immune response to EBV than low-grade LYG. Treatment for high-grade illness has largely involved combination immunochemotherapy, following a paradigm similar to that for other aggressive lymphomas, including EBV+ diffuse large B-cell lymphoma (DLBCL). More aggressive combined chemotherapeutic regimens were ultimately believed to be required to control the disease better and avoid the progression to overt lymphoma despite the promising early success of single-agent chemotherapy with corticosteroids.
-
Combined Immunotherapy - Patients with high-grade LYG in the prospective NCI study receive DA-EPOCH-R (dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, and rituximab) as their primary therapy once every three weeks for up to six cycles of treatment. According to preliminary data from the 18 primary DA-EPOCH-R-treated patients, this regimen is very effective in treating high-grade illness, with more than 75 % of evaluable patients showing signs of improvement (overall response rate, 77 %; 41 % CR).
-
Targeted Therapies - It has been demonstrated that targeted substances, such as immunomodulatory medicines and histone deacetylase inhibitors (HDACis), can promote the expression of the EBV lytic-phase gene and make EBV+ lymphoma cells more susceptible to the lethal effects of antiviral medications. In aggressive B-cell lymphomas, HDACis and immunomodulatory medicines have shown single-agent action. In an early clinical investigation, the HDAC Nanatinostat, in combination with Ganciclovir, caused clinical responses in EBV+ B- and T-cell lymphomas.
For Relapse or Progression:
-
Crossover Treatment - Due to LYG's impaired immune surveillance of EBV, immunochemotherapy or immunological modulation frequently results in relapses with low-grade disease or progression to high-grade disease in cases of high- and low-grade disease, respectively. Patients who advanced after primary IFN therapy and those who did not achieve CR following DA-EPOCH-R were eligible to switch to alternative therapy in the prospective NCI research.
-
Hematopoietic Stem Cell Transplantation (HSCT) - Used to treat patients with refractory LYG or who have experienced numerous relapses. Notwithstanding the drawbacks of this small series and the possibility of selection bias, HSCT should be taken into account in patients who are healthy enough to receive it, given the dismal prognosis of patients with numerous relapses or refractory disease.
Conclusion
Without proper diagnosis and treatment, lymphomatoid granulomatosis might proceed to overt EBV-positive lymphoma, central nervous system illness, or progressive pulmonary failure. Modern advancements in our knowledge of the biology of LYG, notably the precise part played by EBV in its pathogenesis, hold hope for the creation of better management techniques.
